Rothschild & Co Upgrades CME Group to Buy, Raises Price Target to $323

Benzinga Newsdesk www.benzinga.com Positive 79.4%

Neg 0% Neu 0% Pos 79.4%

Rothschild & Co analyst Simon Clinch upgrades CME Group (NASDAQ:CME) from Neutral to Buy and raises the price target from $316 to $323.